<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="ijerph-17-01395-t003" orientation="portrait" position="float">
 <object-id pub-id-type="pii">ijerph-17-01395-t003_Table 3</object-id>
 <label>Table 3</label>
 <caption>
  <p>Characteristics of included studies on economic outcomes due to AMR.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author by Disease</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Year</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Site</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Size</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design/Method</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Quality Assessment</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malaria</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phillips et al. [
     <xref rid="B78-ijerph-17-01395" ref-type="bibr">78</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1996</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simplifying assumptions and illustrative calculations</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The use of quinine versus chloroquine as first-line therapy in 150 million patients with malaria would increase spending by as much as $100 million.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lubell et al. [
     <xref rid="B79-ijerph-17-01395" ref-type="bibr">79</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All malaria-endemic areas</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decision tree model</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The predicted medical costs for retreatment of clinical failures and for management of severe malaria exceed US$32 million per year. Productivity losses resulting from excess morbidity and mortality were estimated at US$385 million for each year during which failing ACT remained in use as first-line treatment.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tuberculosis</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pooran et al. [
     <xref rid="B80-ijerph-17-01395" ref-type="bibr">80</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">South Africa</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cost analysis</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Assuming adherence to national DR-TB management guidelines, the per patient cost of XDR-TB was $26,392, four times greater than MDR-TB ($6772), and 103 times greater than drug-sensitive TB ($257).</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pichenda et al. [
     <xref rid="B81-ijerph-17-01395" ref-type="bibr">81</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cambodia</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">277</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional survey</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The mean total household cost for TB patients was $477, compared to $1525 in MDR-TB cases.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White et al. [
     <xref rid="B82-ijerph-17-01395" ref-type="bibr">82</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1996–1999</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The mean cost of managing a case of pulmonary MDR TB was in excess of 60,000 pounds sterling and for sensitive disease it was 6040 pounds sterling.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rouzier et al. [
     <xref rid="B83-ijerph-17-01395" ref-type="bibr">83</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2007</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ecuador</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">118</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional survey</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Among 104 non-MDR-TB patients, total TB-related patient costs averaged US$960 per patient, compared to an average total cost of US$6880 for 14 participating MDR-TB patients.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marks et al. [
     <xref rid="B84-ijerph-17-01395" ref-type="bibr">84</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2005–2007</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Population-based study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average hospitalization cost per XDR-TB patient (US$285,000) was 3.5 times that per MDR-TB patient (US$81,000), in 2010 dollars</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marks et al. [
     <xref rid="B85-ijerph-17-01395" ref-type="bibr">85</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2005–2007</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">135</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Direct costs, mostly covered by the public sector, averaged $134,000 per MDR TB and $430,000 per XDR TB patient; in comparison, estimated cost per non-MDR TB patient is $17,000.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Krentz et al. [
     <xref rid="B86-ijerph-17-01395" ref-type="bibr">86</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2007–2011</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Canada</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An observational cohort study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients with no resistance had mean PPPM costs of CDN 1058, by contrast with the CDN 1291 costs of patients with secondary/acquired resistance. Mean costs for one, two or three ARV class resistance was CDN 1278, 1337 and 1801, respectively.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Martin S. [
     <xref rid="B87-ijerph-17-01395" ref-type="bibr">87</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2007</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total annual costs ranged from $31 700 for a patient on a 1st-line highly active antiretroviral therapy (HAART) regimen to $42,600 on 6th-line.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Meenan RT. [
     <xref rid="B88-ijerph-17-01395" ref-type="bibr">88</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2010</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total mean healthcare costs were $35,000 higher for patients on a 3rd- or greater line treatment regimen compared to patients on a 1st- or 2nd-line treatment regimen.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>NR, not reported.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
